You are here

Roche

Roche reports positive Phase III data for breast cancer therapy

Roche reports positive Phase III data for breast cancer therapy

Clinical Trials Arena

clinical trials

metastatic breast cancer

Flag link:

Genentech's MS drug on partial hold in US after liver enzyme elevations in 2 patients

Genentech's MS drug on partial hold in US after liver enzyme elevations in 2 patients

Fierce Biotech

multiple sclerosis

clinical trials

Flag link:

Roche joins obesity drug chase with $2.7B deal for startup Carmot

Roche joins obesity drug chase with $2.7B deal for startup Carmot

BioPharma Dive

Carmot Therapeutics

Flag link:

3 standout digital innovations in pharma this year

3 standout digital innovations in pharma this year

Pharma Voice

Boehringer Ingelheim

Flag link:

Roche’s Genentech partners with Nvidia in AI drug deal

Roche’s Genentech partners with Nvidia in AI drug deal

BioPharma Dive

artificial intelligence

Flag link:

A year after Roche's Alzheimer's failure, scientists reflect on what could have been

A year after Roche's Alzheimer's failure, scientists reflect on what could have been

Fierce Biotech

Alzheimer's disease

Flag link:

European regulator endorses high-dose version of Bayer eye drug Eylea

European regulator endorses high-dose version of Bayer eye drug Eylea

Reuters

Flag link:

Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo

Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo

Fierce Pharma

Flag link:

Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

BioPharma Dive

Flag link:

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Motley Fool

ulcerative colitis

Crohn's Disease

Flag link:

FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

BioSpace

retinal vein occlusion

Flag link:

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

Reuters

Flag link:

Roche pays $7.1B to Roivant for rights to Telavant’s IBD candidate

Roche pays $7.1B to Roivant for rights to Telavant’s IBD candidate

BioSpace

ulcerative colitis

Crohn’s disease

Flag link:

Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options

Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options

OBR Oncology

non-small cell lung cancer

Flag link:

Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific

Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific

Fierce Biotech

diabetic retinopathy

bispecific antibodies

Flag link:

Roche's Q3 sales down 3% on currency headwinds, drop in COVID sales

Roche's Q3 sales down 3% on currency headwinds, drop in COVID sales

Reuters

Flag link:

Roche pays $50M upfront to Monte Rosa in molecular glue deal

Roche pays $50M upfront to Monte Rosa in molecular glue deal

Fierce Biotech

protein degradation

Flag link:

Roche builds gene therapy portfolio with SpliceBio deal

Roche builds gene therapy portfolio with SpliceBio deal

Pharmaphorum

Spark Therapeutics

inherited retinal disease

Flag link:

Amid Eylea showdown, Roche's Vabysmo shows durability in retinal vein occlusion

Amid Eylea showdown, Roche's Vabysmo shows durability in retinal vein occlusion

Fierce Pharma

retinal vein occlusion

Flag link:

Roche preps for filings after subcutaneous Ocrevus matches up to IV formulation in phase 3 study

Roche preps for filings after subcutaneous Ocrevus matches up to IV formulation in phase 3 study

Fierce Pharma

multiple sclerosis

clinical trials

Flag link:

Pages